bound to MHC molecules. The co-recognition of peptide and MHC proteins is among the most influential bio logical discoveries of the twentieth century [1] [2] [3] . This model explained that the functional specificity of T cells for peptides and MHC proteins results from direct contact of a TCR with a hybrid surface formed by a peptide and an MHC molecule. Furthermore, the high level of polymorphism in MHC Ia genes explains, at least in part, why individuals typically use different αβ TCRs to respond to the same antigen, thereby forming highly distinct (or private) TCR repertoires. To date, nearly all technologies that seek to manipulate or detect human αβ T cell responses are based on the principles of peptide-MHC co-recognition. For example, vaccine subunits are derived from proteins, and antigenic epitopes that control T cells during infection, vaccination, cancer and autoimmune diseases are mapped through peptide sequencing. However, peptide-MHC complexes are not the sole targets of human T cell responses. It is increasingly appreciated that a substantial proportion of the overall αβ T cell repertoire recognizes antigens presented by non-polymorphic antigen-presenting molecules that are encoded within the MHC locus (such as HLA-E antigen display platforms and propose that T cell activation can occur by an unexpected mechanism of absence of interference with an approaching TCR. New evidence shows that T cells recognizing CD1 or MR1 proteins are abundant in humans, supporting the use of lipid and small-molecule antigens as a new approach to therapy.
A primary activation signal for T cells occurs when αβ T cell receptors (TCRs) contact peptide antigens bound to MHC molecules. The co-recognition of peptide and MHC proteins is among the most influential bio logical discoveries of the twentieth century [1] [2] [3] . This model explained that the functional specificity of T cells for peptides and MHC proteins results from direct contact of a TCR with a hybrid surface formed by a peptide and an MHC molecule. Furthermore, the high level of polymorphism in MHC Ia genes explains, at least in part, why individuals typically use different αβ TCRs to respond to the same antigen, thereby forming highly distinct (or private) TCR repertoires. To date, nearly all technologies that seek to manipulate or detect human αβ T cell responses are based on the principles of peptide-MHC co-recognition. For example, vaccine subunits are derived from proteins, and antigenic epitopes that control T cells during infection, vaccination, cancer and autoimmune diseases are mapped through peptide sequencing. However, peptide-MHC complexes are not the sole targets of human T cell responses. It is increasingly appreciated that a substantial proportion of the overall αβ T cell repertoire recognizes antigens presented by non-polymorphic antigen-presenting molecules that are encoded within the MHC locus (such as HLA-E [4] [5] [6] or outside the MHC locus (such as CD1a 7, 8 , CD1b 9 , CD1c 10 , CD1d 11 and MHC class I-related protein (MR1) 12, 13 ). Moreover, αβ 14 , γδ 15, 16 and δ/αβ 17 T cells can all recognize CD1 proteins. Here, we highlight recent studies of CD1 antigen display that provide clear exceptions to the principles of peptide-MHC co-recognition. We focus on the asymmetric nature of human CD1
antigen display platforms and propose that T cell activation can occur by an unexpected mechanism of absence of interference with an approaching TCR. New evidence shows that T cells recognizing CD1 or MR1 proteins are abundant in humans, supporting the use of lipid and small-molecule antigens as a new approach to therapy.
The CD1 genes
In early work, antibodies were used to identify two β2-microglobulin-associated heavy chains; these were later named MHC class I and CD1 proteins 18 . Human CD1 genes are located on chromosome 1 (REF. 19 ) and encode five CD1 isoforms, which were assigned to group 1 (CD1a, CD1b, CD1c and CD1e) or group 2 (CD1d) on the basis of sequence homology 20 . A second reason for designating two groups is that, whereas CD1d is constitutively expressed 21 , the group 1 CD1 genes are inducible and coordinately regulated primarily by myeloid cells 22, 23 . CD1 genes are present in all placental mammals, birds and marsupials 24 (FIG. 1) . The differing size and composition of CD1 loci in modern mammals probably reflect selective pressure owing to immune function [25] [26] [27] [28] [29] . Moreover, the retention of many CD1 genes, with some species encoding more than ten CD1 genes, is consistent with the existence of non-redundant functions for each CD1 isoform. The exception is muroid rodents, which encode two copies of one isoform: namely, CD1d1 and CD1d2.
Human CD1 proteins.
It is now clear that each type of CD1 protein has a distinct biological function 30 . For example, CD1e is a soluble lipid transfer protein 31 , whereas CD1a, CD1b, CD1c and CD1d are membrane-bound 
Accessory portals
Small gaps present in the side or bottom of the clefts present in CD1b (Cʹ portal) and CD1c (Dʹ and Eʹ portals). Whereas the main Fʹ portal is present in all CD1 proteins and allows antigen contact with T cell receptors (TCRs), accessory portals probably have a separate sizing function that allows lipids to partially escape from the interior of the cleft at a site distant from TCR contact.
Tetramers
Reagents comprised of a fluorophore-conjugated core surrounded by four antigen-presenting molecules (for example, MHC class l, CD1 or MR1). Antigen-loaded tetramers bind antigen-specific T cell receptors with sufficient avidity so that antigen-specific T cells can be directly counted or isolated by flow cytometry.
antigen-presenting molecules. Each type of CD1 protein takes different routes through cells 32 and has different expression patterns -B cells express CD1c and CD1d; myeloid dendritic cells (DCs) express CD1a, CD1b, CD1c and CD1d; epithelial cells express CD1d; and Langerhans cells express CD1a 21 . The transcription of the group 1 and group 2 CD1 genes is differently induced by microbial stimuli, with bacterial stimuli selectively upregulating the expression of group 1 CD1 proteins by myeloid DCs 23, 33 . Furthermore, each human CD1 protein has a different antigen-binding cleft architecture, with differing numbers of pockets (known as Aʹ, Cʹ, Fʹ and Tʹ pockets) and accessory portals (known as Cʹ and Dʹ/Eʹ portals) 34 . As mice lack group 1 CD1 proteins, most studies have focused on the recognition of CD1d by a population of CD1d-dependent αβ T cells known as natural killer T (NKT) cells. The growing appreciation of functional divergence of CD1 isoforms provides a clear rationale for the development of new tools to study CD1a, CD1b and CD1c proteins in vivo or ex vivo, including human group 1 CD1 tetramers 9,10,35 and CD1-transgenic mice 36 or small animals, such as guinea pigs, that naturally express group 1 CD1 proteins 37, 38 .
CD1-presented antigens
Lipids. T cell responses to CD1 molecules were discovered during studies of Mycobacterium tuberculosis 39 . The peptide-MHC co-recognition model predicted that this pathogen would generate peptide antigens, but studies of the whole bacteria showed that antigens could be extracted into organic solvents that exclude proteins. Indeed, in 1994, CD1b was reported to present free mycolic acid, a long-chain α-branched, β-hydroxy fatty acid that is characteristic of mycobacteria 40 . Many more types of lipid antigen have since been identified, including glycolipid, phospholipid, glycophospholipid, sulfolipid and lipopeptide antigens 41 . Most antigens are amphipathic lipids that contain one, two or three aliphatic hydrocarbon chains and a hydrophilic head group comprised of polar or charged moieties (FIG. 2) . The head groups vary in size, ranging from the small carboxylate moiety in free mycolic acid to the large polysaccharides in gangliosides. Head groups protrude from the CD1 cavity to bind TCRs, whereas the long and flexible alkyl chains can insert deeply and bend to match the shape of the CD1 cavities 42 . Lipid interactions with the interior of the groove are relatively nonspecific, as one ligand can insert in different orientations, but in general, the head group positioning is more precise 43 .
Small molecules.
As an exception to the general rule that CD1-dependent T cell activation occurs in response to amphipathic lipids, phenyl 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonate (PPBF) is a synthetic, non-lipid small molecule that activates T cells via CD1d 44 . The molecular mechanism of PPBF action is not fully understood and was difficult to predict because it lacks flexible aliphatic chains and a discrete hydrophilic head group (FIG. 2) . Furthermore, the TCR co-recognition model proposes that antigens must exceed the CD1 cleft volume so that they can protrude for direct TCR contact. However, PPBF is less than half the mass of most antigens and is smaller than the volume of the CD1d cleft. Thus, PPBF raised questions about the role of particularly small or non-lipid antigens in the activation of T cells; this issue was later highlighted through studies of skin oils and riboflavin-derivative antigens (discussed below). The discovery of avian CD1 orthologues indicates the existence of ancestral CD1 genes before the bird-mammal split, and CD1 genes are universally or widely conserved in mammals. The number of CD1 genes differs in rabbits 26 , mice, guinea pigs, primates, dogs 29 , cattle 126 , pigs 28 , horses 25 and chickens 127, 128 . For guinea pigs, we discovered one CD1 gene in the updated genome, in addition to the published genes 38, 129 , which we named after the closest human CD1 orthologue (CD1a). All group 1 CD1 proteins are absent in mice, creating a need for additional experimental models to study CD1a, CD1b and CD1c. Nature Reviews | Immunology
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Glucose monomycolate Skin oils. In 1989, T cells with autoreactivity to CD1a and CD1c proteins were discovered 22 . Based on the corecognition model, it was assumed that this autoreactivity derives from TCR contact with defined lipid autoantigens bound in the CD1 cleft. Recently, this assumption was tested using a human CD1a-autoreactive αβ T cell line (BC2) to isolate CD1a-binding antigens produced in human cells and tissues 45 . CD1a-binding autoantigens preferentially accumulate in the skin 45 , and this is consistent with studies showing that CD1a-autoreactive T cells home to the skin and that CD1a expression is higher in the skin than in other organs 7 . Extraction of whole cells or lipid-CD1 complexes with chloroform, followed by mass spectrometry, identified the CD1a-presented autoantigens as extremely hydrophobic skin oils: namely, wax esters, squalene and triacylglycerides 45 (FIG. 2) . Unlike amphipathic lipids, oils lack hydrophilic head groups composed of sugars or other polar elements. Similar to PPBF, the small molecular volume of oils raises questions about how or whether they could protrude above the CD1 presentation platform to contact TCRs.
Scaffold lipids.
Enzymes trim the carbohydrate moieties of glycolipids in antigen-presenting cells (APCs) 10, 46, 47 , and nearly all antigens that bind MHC class Ia mol ecules are trimmed to fit the groove. However, the alkane lipid moieties of CD1-presented antigens are chemically unreactive and are not trimmed to fit ) is nearly 50% larger than the cavities in other CD1 isoforms (FIG. 3 ), but few correspondingly large self lipids (~76 carbons) are present in mammalian membranes. When lipid ligands were eluted from CD1a, CD1b, CD1c and CD1d produced in human cells, the average mass of ligands released from CD1b was not larger than that released from CD1 proteins with smaller clefts 50 . A straightforward explanation would be that two or more lipids bind CD1b concomitantly. An early study showed that phosphatidylinositol bound in the 'upper chamber' of CD1b and that two unknown ligands (possibly detergents) were present in the Tʹ tunnel 42 . Crystal structures of lipid-CD1b complexes containing phosphatidylcholine or sulfo glycolipid later showed that electron densities corresponding to ligands in the cleft were larger than the known size of added ligands, implying the existence of chaperone lipids that bind CD1b alongside the added ligand 51, 52 . Furthermore, by comparing crystal structures of CD1b molecules bound to various ligands, the positioning of CD1b residues near the TCR contact surface was influenced by ligand size, a finding that was interpreted as ligand sliding 51 . Along with similar studies of CD1d 53 , these studies provide an explicit structural mechanism by which the size of the lipid within the groove could alter TCR contact sites on the outer surface of the CD1 complex (FIG. 3a) . Mass spectrometry studies identified the endogenous chaperone lipids as diacylglycerides and deoxydihydroceramides 50,51 (FIG. 3b) . These lipids were designated as scaffold lipids to emphasize that they bind below the antigen and can be thought of as pushing the antigen towards the TCR 50 . Scaffold lipids are similar to class II-associated invariant chain peptide (CLIP), except that scaffold lipids only partially occupy the CD1b cleft and so function as a sizing mechanism rather than blocking all ligand exchange. These insights might explain the differing selectivity of CD1b for small (32-carbon) and large (80-carbon) ligands . b | CD1b-binding natural scaffold lipids -diacylglycerides and deoxydihydroceramidesare unusually hydrophobic self lipids. The term 'scaffold' refers to the location of one particular kind of spacer lipid, which is located at the bottom of the CD1b groove and lifts of the sulfoglycolipid antigen towards the surface.
Secretory pathway
A series of protein transport reactions in which newly folded proteins transit from the endoplasmic reticulum to the Golgi apparatus and to the cell surface. For CD1, this pathway provides self lipids that are loaded onto CD1 proteins at neutral pH.
Endosomal recycling
A process by which CD1 proteins shuttle from the cell surface to the endosomal network and back. CD1b, CD1c and CD1d proteins contain tyrosine-containing motifs in their cytoplasmic tails that mediate binding to adaptor proteins and transport to endosomes and lysosomes, where lipids derived from outside the antigen-presenting cell bind CD1 proteins at neutral or acidic pH.
Spacer lipids
Hydrophobic compounds that bind alongside antigenic lipids and fill up part of the CD1 cleft that is not occupied. when present in different cellular subcompartments 49 . The loading of large ligands is expected to require the removal of the antigen and the scaffold lipid from the upper and lower chambers 51 . This lipid exchange process is promoted by acid pH in lysosomes 49, 54 , which uncouples tethering amino acid side chains located on the top and side of the CD1b groove (at positions 80 and 86, respectively). These effects relax the CD1b conformation, creating a larger portal for exogenous antigen entry and ligand exit from the cleft 55 . By contrast, loading of small lipids is now thought to require emptying of the upper chamber only 50 and occurs efficiently at neutral pH, when the interdomain tethers are intact 42 . Direct measurements of lipid exchange within CD1 are limited [55] [56] [57] [58] . However, these findings suggest a working model in which short self lipids can be loaded together with scaffold lipids at neutral pH in the secretory pathway, followed by the capture of larger foreign lipids during endosomal recycling.
Mucosal-associated invariant T cells (MAIT cells). T cells that
Spacer lipids. The more general problem of lipid sizing for all CD1 isoforms is accomplished through spacer lipids and accessory portals. Unlike the upward push of scaffold lipids in CD1b, 'spacer lipid' is a more general term for any lipid that occupies the groove together with antigens. For example, certain CD1d 59 , CD1c 10 and CD1a 60 crystal structures show electron densities that correspond to the lipid antigen present only in the Fʹ pocket with spacer lipids occupying the Aʹ pocket (FIG. 2) . At the other end of the size range, large lipids probably protrude through small gaps in the lateral walls of CD1b and CD1c, known as the Cʹ and Dʹ/Eʹ portals, respectively 42, 61 . Unlike the Fʹ portal, which allows lipids to protrude onto the antigen display platform, these accessory portals are located beneath the α-helices and so allow the lipid to escape from a position that is distant from the TCR. Also, CD1a and CD1c molecules have unnamed notches in the lateral wall of the Fʹ pocket that could allow lateral escape of bound lipids 61, 62 . In summary, whereas the MHC antigen display system trims antigens to fit, the CD1 molecules use scaffold lipids, spacer lipids, accessory portals and notches to fine-tune lipid ligands to cleft volume.
MR1-presented antigens
Vitamin B derivatives. Similar to CD1 molecules, MR1 molecules are comprised of non-polymorphic heavy chains bound to β2-microglobulin. For many years, MR1 molecules were known to mediate the activation of mouse and human mucosal-associated invariant T cells (MAIT cells) in response to certain micro organisms 12, 13, 63 . Using recombinant MR1 proteins to capture ligands derived from culture media and bacteria, the ligands were recently identified as a photodegradation product (6-formylpterin (6-FP)) of folic acid (vitamin B 9 ) 64 . MR1-presented antigens are modified metabolites derived from the riboflavin (vitamin B 2 ) pathway: 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-oxoethylideneamino)-6-D-ribityl aminouracil (5-OE-RU), respectively 65 . Ribityl lumazines and ribityl pyrimidines lack aliphatic hydrocarbon chains (FIG. 2) , reinforcing the concept that T cells can respond to small molecules that are neither peptides nor lipids.
MR1 antigen display.
Crystal structures of 5-OP-RU-MR1 and 6-FP-MR1 complexes show an 'aromatic cradle' within the Aʹ pocket of the MR1 antigen-binding cleft that is well suited for binding the derivatives [64] [65] [66] [67] ( FIG. 4) . At the base of this hydrophobic Aʹ pocket is a lysine residue (Lys43) that forms a Schiff base with 6-FP, 5-OP-RU and related ligands. In contrast to the substantially protruding head groups of CD1-presented antigens, these vitamin B derivatives are closely sequestered within the MR1 cleft, such that only a tiny proportion of the riboflavin derivative is exposed for TCR recognition 64, 68 (FIG. 4) .
Origin of MR1-presented antigens. Riboflavin derivatives can be considered as foreign antigens because they arise in certain bacteria and fungi. However, the most potent MAIT cell ligands derive from covalent conjugation of a riboflavin precursor to methylglyoxal or glyoxal and other host or microbial intermediates, so that the resulting product is a hybrid neo-antigen 65 . A central question now is whether MAIT cells mainly recognize vitamin B derivatives or also see other types of antigen. The range of bacterial and fungal organisms that activate MAIT cells 12, 13, 63 corresponds well to the range of organisms with riboflavin pathways 64 . This observation, along with the detection of large numbers of MAIT cells by MR1 tetramers bound to one type of ribityl pyrimidine ligand (5-OP-RU), suggests that one known antigen broadly supports recognition by MAIT cells. Furthermore, deletion of either of the two riboflavin biosynthetic genes (ribA and ribG) from Lactococcus lactis, or related genes in Escherichia coli, ablates T cell recognition, indicating that other antigens do not exist in these species 65, 69 . However, crystal structures of 5-OP-RU-MR1 complexes show that the Fʹ pocket of MR1 remains empty, so larger ligands that are yet to be discovered might also bind within MR1.
TCR recognition of peptides, lipids and metabolites
Ternary crystal structures comprised of TCRs bound to CD1 (REF. 70) or MR1 protein complexes 71 can be compared with the 34 unique structures of TCR-MHC class I complexes 70 . TCR recognition of α-galactosylceramide (αGalCer) 14 , 5-OP-RU 71 or an 11-mer peptide 72 involves prototypical co-recognition interactions: that is, the approaching TCR contacts a hybrid surface formed by the α-helical regions of the antigen-presenting molecule and the ligand, sitting in the cleft between the helices (FIG. 4) . However, recent structures of αβ, γδ and δ/αβ TCRs have revealed clear and fundamental differences between CD1 and MHC antigen display. The studies detailed below describe unexpected modes of recognition that fall outside the co-recognition paradigm.
Left-right asymmetry of CD1 architecture. The key difference between MHC and CD1 proteins relates to the absence or presence of lateral symmetry in the antigen display platform (FIG. 5a) . In MHC proteins, the TCR contact region can be imagined as a platform bisected by a plane that is perpendicular to the axis of the groove. The groove is accessible on both sides of the Nature Reviews | Immunology (FIG. 5a, green) . By contrast, the four types of CD1 molecules show a fundamental left-right asymmetry (FIG. 5a, red and green) . At one end of the CD1 cleft, located above the Aʹ pocket, amino acid side chains (interdomain tethers) reach across the space between the α1 and α2 helices to form the Aʹ roof 42, 61, 62, 73 . Above the Fʹ pocket and on the right-hand side of the CD1 molecule, the hydrophilic head groups of the bound antigen protrude upwards to contact the TCR (FIG. 5a,  green) . Thus, the CD1 display platform is dominated by the outer surface of the CD1 protein on the left side and the lipid ligand on the right side.
A second general point of contrast between MHC and CD1 proteins is the extent to which antigens are exposed to the outer surface. Whereas MHC class I grooves are exposed to solvent across their lateral dimension for more than 20 Å, as measured from the interior cusp of the Aʹ pocket to the Fʹ pocket, the equivalent opening in CD1 is only ~10-13 Å wide (FIG. 5a) . On the basis of its small size and rounded shape, this opening is known as the Fʹ portal. Whereas the term 'groove' accurately describes the long, laterally oriented and uncovered nature of the antigen-binding cleft in MHC molecules, CD1 clefts are much less like grooves because the Aʹ roof covers much of the top of the antigen-binding cleft. The cavity looks like an empty boot viewed from the side: broad at the bottom but tapering to a narrower opening on the right (FIG. 5b) .
Influence of asymmetry on antigen display. With some notable exceptions 74, 75 , many TCR footprints on MHC class I molecules are located near the centre of the platform 70 . The central location and extensive exposure of peptides on MHC, along with the relatively large size of TCR footprints (1,200-2,400 Å 2 ), favours substantial contact of the TCR with exposed peptide 70 . By contrast, the asymmetrical locations of the Fʹ portals on CD1 molecules mean that the contribution of the ligand is pushed towards the edge of the platform. The portals in CD1 proteins are smaller than the grooves in MHC proteins in all cases reported to date, but the head groups of CD1 ligands vary in size. After traversing the Fʹ portal, head groups can lean leftwards and occupy a central location on CD1 or lean rightwards to reside at the extreme right edge of CD1 (FIGS 4, 5) . Therefore, individual TCRs could preferentially contact the CD1 protein on the left or instead take a central or right-sided approach to mainly contact the lipid ligand. This left-right shift hypothesis is attractive because it might explain why so many CD1-reactive T cells show mixed antigen dependency and autoreactivity 7, 8, 22, [76] [77] [78] . Furthermore, lateral shifts in TCR footprints might explain the varied dependence on antigen for individual TCRs or the predominant reliance on TCR α-or TCR β-chains for antigen recognition. Although there are still only a few crystal structures available, the TCR footprints on CD1 complexes are positioned off-centre with some near the extreme left or right side of the platform, creating modes of antigen recognition that are not known from the MHC system 70 .
NKT cell TCR footprints on CD1d. In contrast to the typically diagonal-orthogonal orientation of TCRs on MHC class I complexes, the first structure of a lipidCD1d-TCR complex revealed that the TCR is oriented in parallel with the axis of the cleft 14 (FIG. 4) . The galactose head group of the ligand αGalCer rests on the centreright side of CD1d. The TCR is markedly right-shifted such that the TCR α-chain is positioned above the galactose moiety and the TCR β-chain is positioned to the far right such that it makes minimal contact with CD1d and no contact with the antigen. This extreme right-sided footprint explains why the TCR α-chain is dominant for the antigen specificity of invariant NKT cells. Many other type I NKT cell TCRs also assume this right-sided footprint when recognizing other α-or β-linked hexosylceramide or isogloboside antigens 79 . By contrast, a variable (type II) NKT cell TCR known as XV19 showed an orthogonal docking and left-of-centre footprint. As it is docked over the Aʹ roof, the XV19 TCR makes most contact with CD1d, but it also makes some contact with the sulfatide head group near the centre of the platform. Overall, these glycolipid-CD1d-TCR structures illustrate the left-right shift and the differing rotation of αβ TCRs docking on CD1d molecules. Although CD1c has not been co-crystallized with TCRs, alanine scanning mutagenesis suggests that individual αβ TCRs also use different left-sided or right-sided footprints 80 .
Absence of interference.
The examples discussed above show how TCRs bind to exposed head groups. However, CD1a-presented skin oils lack obvious hydrophilic head groups for the usual hydrogen bonding or chargecharge interactions between TCR and antigen 1, 2, 81 (FIG. 2) .
Moreover, CD1a-autoreactive T cell clones lack the fine antigen specificity that is seen for recognition of glyco lipids and peptides 78, 82 and, instead they cross-react with several hydrophobic molecules, including methyl fatty acids, triacylglycerides and wax esters 45 . These findings suggest that the stimulatory compounds do not directly contact the TCR. Indeed, the small size and hydrophobic nature of squalene and related lipids might allow them to nest inside the CD1a groove, so that they do not interfere with TCR binding to the outer surface of CD1a; we have termed this mode of activation 'absence of interference' (REF. 45 ).
Supporting this hypothesis, CD1a proteins acquire antigens over time, and when emerging at the cell surface, they predominantly carry antigens with large hydrophilic head groups, including sphingomyelin. In fact, sphingomyelin and other non-permissive ligands block CD1a autoreactivity in vitro 45 . Unlike other CD1 isoforms, which extensively recycle to lysosomes, CD1a molecules mainly reside at the surface of epidermal Langerhans cells and capture exogenous ligands 83, 84 . Wax esters accumulate in the cornified epithelium, and squalene is a major lipid in sebum, so both of these self ligands accumulate within or outside of the epidermis and not within APCs. Accordingly, the absence of interference model predicts antigen-presenting molecules use an asymmetrical antigen display platform. In human CD1 proteins, the α1 and α2 helices connect to form Aʹ roofs, which cover approximately half of the cleft. These roof structures prevent direct TCR binding to antigen positioned on the left side of the platform. Antigens such as sulfatide 62 , ganglioside M2 (REF. 42 ) and phosphomycoketide 61 protrude from the open end of the cleft through a rounded opening known as the Fʹ portal. The hydrophilic head groups of individual antigens vary in size so that they can protrude minimally or extensively. The site of antigen protrusion is on the right side of the platform, but antigens with large head groups can pivot either to the left, creating an epitope near the centre of CD1, or to the right, creating an ectopic epitope at the extreme right. b | The transparent surface of the CD1b 'groove' demonstrates that it is not a groove-like structure that is broadly exposed to solvent. Instead, the shape of CD1 grooves resembles a boot viewed from the side because the Aʹ roof creates a constricted, portal-like connection with the TCR contact surface. Nature Reviews | Immunology . The nested oils might stabilize the interior of the cleft and change the outer shape of the CD1a complex, permitting allosteric changes that favour TCR binding. Alternatively, permissive ligands might function by displacing larger non-permissive lipids to create space on the outer surface of CD1a for the approaching TCR.
TCR recognition of CD1a
Permissive ligands. The absence of interference theory has recently been tested through the study of ternary interactions between lipid, CD1a and TCR. Tetramers usually require loading with homogeneous antigen so that multiple arms of the tetramer carry the same antigen, creating the avidity needed to bind an antigen-specific T cell 85 . Therefore, it was surprising that a CD1a-autoreactive TCR known as BK6 could bind CD1a tetramers loaded with diverse self lipids 58 . Using the BK6 TCR to pull down bound lipid-CD1a complexes, lipidomic profiling detected hundreds of distinct lipids. Because many chemically distinct lipid ligands permitted TCR binding to CD1a, they were termed permissive ligands. Subtractive analysis showed that sphingomyelin was specifically excluded from lipid-CD1a-TCR complexes and blocked tetramer staining of BK6 TCR + cells, indicating that sphingomyelin is a non-permissive ligand 45, 58 . This unusual TCR response to most but not all lipid ligands was explained by the ternary structure of BK6 TCR-lipid-CD1a. The BK6 TCR has an extreme left-sided footprint over the Aʹ roof of lysophosphatidylcholine (LPC)-CD1a complexes (FIG. 6a, red) . LPC does not fully nest within the cleft, but its head group leans to the right as it traverses the Fʹ portal, exposing a large area on the Aʹ roof to which the TCR can bind (FIG. 6a,b) . Importantly, the BK6 TCR contacts the Aʹ roof but not the LPC ligand. Thus, CD1a is the antigenic target, and LPC is a permissive ligand that allows the TCR to contact CD1a in the absence of interference.
A second structure of the BK6 TCR binding to CD1a carrying diverse endogenous ligands (endog-CD1a) also illustrates absence of interference (FIG. 6b) . The endogCD1a-BK6 TCR structure shows electron density in the Fʹ pocket that corresponds to that of a fatty acid (FIG. 6b,  left) . Unlike the LPC-CD1a structure, but consistent with the nesting hypothesis, the observed electron density does not protrude through the Fʹ portal to the surface. In fact, free fatty acids could be extracted from CD1a-TCR complexes, suggesting that some ligands are small enough to nest within CD1a
58
. Overall, permissive ligands function by two related mechanisms that fit the concept of absence of interference: nesting within CD1a or exiting the portal and turning to the right to become positioned away from the Aʹ roof.
Non-permissive ligands. The molecular mechanisms by which non-permissive ligands disrupt TCR binding are illustrated in binary structures of CD1a bound to sphingo myelin 58 , sulfatide 62 or the mycobactin-like lipopeptide dideoxymycobactin 60 (FIG. 6c) . In CD1a, the Aʹ roof is formed in part by salt bridges between the residues Arg73, Arg76 and Glu154, which tether the α1 and α2 helices. Sphingomyelin, sulfatide and dideoxymycobactin disrupt the intrinsic structure of the Aʹ roof. Thus, large ligands can interfere with TCR contact by inserting themselves within the intrinsic structure of the Aʹ roof or by protruding through the Fʹ portal to a position on top of the Aʹ roof.
Dual mechanisms. Any single CD1a-restricted TCR either does or does not contact lipid, so absence of interference and co-recognition are mutually exclusive mechanisms for individual TCRs. However, it is likely that the broader CD1a-reactive repertoire uses both mechanisms. Recognition of dideoxymycobactin-CD1a probably occurs via co-recognition (FIG. 6c) , as loading of the lipopeptide into CD1a is necessary for TCR binding and this ligand does protrude from the cavity to alter the surface above the Fʹ portal 35, 60, 86, 87 . For other known CD1a antigens, such as sphingolipids and phospholipids [88] [89] [90] , the mechanism of recognition has not been solved structurally, but co-recognition is favoured on the basis of their large head groups. b | Permissive lipid ligands act through absence of interference using two proposed mechanisms. Some endogenous lipids have small head groups that are predicted not to protrude substantially from the groove, whereas LPC does protrude from the groove but takes a rightward position on the surface so that it does not contact a left-binding TCR. c | Based on binary TCR structures 60, 62 , non-permissive ligands -such as sphingomyelin, sulfatide and the mycobactin-like lipopeptide -bind in the groove and are thought to have an anti-antigenic function by blocking TCR docking to CD1a. Non-permissive ligands can disrupt a triad of amino acids (R76, E154 and R73) within the Aʹ roof 58 . β2M, β2-microglobulin.
CD1 molecules bind γδ TCRs
There are many subsets of γδ T cells 91 . In humans, one subset expresses TCRγ variable chain 9 (TRGV9) and TCRδ variable chain 2 (TRDV2) and recognizes soluble antigens, such as alkyl phosphates and alkyl amines [92] [93] [94] , probably indirectly through allosteric modification of the cell surface molecule butyrophilin 3A1 . Other γδ T cell subsets directly target surface molecules-such as endothelial protein C receptor 98 , T10 (also known as CD38 and ADPRC1) and MHC class I polypeptide-related sequence A (MICA) 96 . The first report of CD1-mediated antigen presentation described a response by both αβ and γδ T cells 22 . With a few exceptions 99, 100 , CD1 research focused on αβ T cells, but recent tetramer 101 and crystallography [15] [16] [17] studies have confirmed the γδ TCR-CD1d interaction. The γδ TCR 9C2 (which is composed of TRGV5 and TRDV1) recognizes αGalCer-CD1d complexes (FIG. 4) , whereas the γδ TCR DP10.7 (which is composed of TRGV4 and TRDV1) binds sulfatide-CD1d complexes. Both structures show a left-sided TCR footprint, orthogonal rotation and reliance on binding of tryptophan residues from complementarity-determining region 1δ (CDR1δ) to CD1d. One difference is that the TCR 9C2 uses the CDR3γ loop to bind the protruding αGalCer head group, whereas the TCR DP10.7 uses the hypervariable residues in CDR3δ for all interactions with sulfatide. Several TRDV genes can also be used by αβ T cells, including TRDV4-TRDV8, and share TCRα variable chain (TRAV)-related names 102 . In addition, it has been long known that TRDV1 and TRDV3 genes can join TRAJ and TCRα constant chain (TRAC) genes [103] [104] [105] , but it was unclear how these TRDV gene products contribute to the overall specificity of the 'hybrid' TCRs. A recent study 17 of such a hybrid TCR, composed of a TRDV1 domain fused to the TRAJ-TRAC domain and paired with a TCR β-chain, showed that it binds αGalCer-CD1d using an orthogonal and left-aligned docking mode. Mirroring the γδ TCR 9C2, the TRDV1 CDR1δ loop bound mainly to CD1d, whereas the CDR3β loop bound the galactosyl head group of αGalCer.
Role of CD1 ligands. Although most work on γδ T cells emphasizes direct TCR contact with the monomorphic surfaces of cell surface molecules 91 , crystal structures involving lipid-CD1d complexes suggest that γδ TCRs recognize antigens that are physically displayed. This is supported by the observed contact of the CDR3δ and CDR3γ loops with sulfatide and αGalCer, respectively 15, 16 . Indeed, the highly diverse CDR3 junctional residues might mediate non-cross-reactive recognition of other lipid antigens through direct TCR contact with antigen. An alternative view suggests that the most important interactions are between the γδ TCR and the CD1 molecule itself, rather than between the γδ TCR and the bound ligand. Specifically, the γδ TCR might indirectly detect the presence of any bound ligand in CD1 or the absence of an interfering ligand. Current evidence suggests that both scenarios occur because some γδ T cells seem to be highly dependent on the bound lipid antigen, whereas others seem to be tolerant to many different bound antigens 15, 16, 89, 106, 107 . The left-right shift hypothesis outlined for αβ TCRs (FIG. 5) might also be relevant to γδ TCRs (right panel of FIG. 4) . The two known TRDV1 TCR footprints are left-shifted, and most interactions involve the Aʹ roof of the CD1 molecule. The bound ligands contribute in a small way to TCR contact, which is consistent with the observed partial dependence on ligand for TCR binding. 108, 109 and MAIT cells 110 were discovered by detecting T cells expressing similar αβ TCRs. Only later were they were found to recognize CD1d 111 and MR1, respectively 63 . Now, with the generation of CD1 and MR1 tetramers, responding T cells can be tracked according to antigen specificity rather than TCR expression. By removing TCR gene usage as the means of detection, ligand-loaded tetramers allow broader and unbiased study of all TCRs that recognize a given antigen complex. This approach is already leading to a broadening of the types of TCR that meet the definition of MAIT cells 66, 68 , and it also led to the discovery of two previously unknown T cell types that recognize CD1b 112, 113 . The CD1b-specific TCR repertoire. Both MAIT cells and NKT cells exist as large T cell populations that express nearly identical (invariant) but non-clonal TCRs in a process that occurs among genetically unrelated donors. Thus, the two defining features of these TCRs are intradonor and interdonor TCR conservation, whereas MHC-reactive TCRs generally lack these features. These conserved TCR patterns in NKT cells and MAIT cells derive from germline-encoded variable and joining genes with limited N-region additions to yield stringently conserved α-chains (TABLE 1) .
CD1 and MR1 tetramers
Group 1 CD1 tetramers are now allowing the analysis of CD1a-, CD1b-and CD1c-reactive TCR repertoires. The earliest studies failed to detect intradonor or interdonor conservation in the group 1 CD1-reactive TCR repertoire 7, 114, 115 . These studies found that individual TCRs recognizing CD1a, CD1b or CD1c in combination with various antigens expressed differing variable, joining and diversity segments, suggesting that the group 1 CD1-restricted TCR repertoire is diverse. This finding was often offered as a point of contrast with the stereotyped nature and innate functions of NKT cells and MAIT cells. However, the non-polymorphic group 1 CD1 proteins might be expected to activate similar TCRs present among unrelated individuals. Indeed, when comparisons were simplified to assess the diversity of human TCRs that recognize one CD1 protein (CD1b) paired with one antigen (mycobacterial glucose monomycolate (GMM)), intradonor and interdonor TCR conservation was readily identified (TABLE 1) .
Fulfilling the criterion of intradonor conservation, polyclonal T cells expressed TCRs with highly similar TCR α-chains composed of TRAV1-2 joined to TCRα joining 9 (TRAJ9) paired with an apparently biased population of TCRβ variable chain 6-2 (TRBV6-2) chains 113 . This TCR pattern was seen among unrelated donors, indicating interdonor conservation. Such TCRs showed high affinity for GMM-CD1b complexes 112, 113 . Based on the TCR structure and antigen specificity, such CD1b-reactive T cells were called germline-encoded mycolyl-specific (GEM) T cells 113 . GEM T cells are less frequent in human blood than NKT cells or MAIT cells, but the degree and pattern of TCR conservation is equivalent to that found in these other TCR-defined T cell subsets 113 (TABLE 1) .
A separate population of GMM-reactive T cells with intermediate affinity for CD1b also showed interdonor TCR conservation but with a different TCR pattern and lower affinity for GMM-CD1b 112 . Among these T cell clones derived from patients with tuberculosis, TRBV4-1 was the most frequently used β-chain, and some clones expressed TRAV17. This pattern was seen nearly two decades ago in a clone (known as LDN5) derived from a patient with leprosy 82 . Thus, the newly discovered, polyclonal T cells were designated LDN5-like T cells. This name indicates that this TCR is not a unique or private TCR, as previously thought, but is instead an in vivoexpanded T cell type (TABLE 1) . Thus, TCR bias and affinity define two compartments of the CD1b-reactive repertoire.
GMM is the first antigen to be systematically investigated for TCR diversity in the group 1 CD1 system, and it revealed two invariant T cell types. At a minimum, human CD1 proteins bind hundreds of ligands 50 . Thus, considering all available lipid-CD1 combinations, it is possible that the CD1 system supports a network of interdonor-conserved TCRs. Supporting this idea, recent studies of human TCRs isolated using CD1c tetramers loaded with mycobacterial phosphomycoketides show frequent expression of TRBV7-8 + and TRBV7-9 + TCRs 80 (TABLE 1) . Sequencing of the TRAV1-2 + T cell repertoire identified 16 additional TCR α-chains that do not match the known MAIT cell and GEM T cell TCR motifs but are conserved among the majority of human donors 116 . If conserved TCR patterns could be traced back to disease-related antigens (such as mycobacterial GMM), invariant TCRs might be used for immunodiagnosis.
Towards therapy
The immunodominant peptides for any pathogen or autoimmune disease differ according to the MHC haplo types of the individual patients. Therefore, peptidebased immunomodulation is not broadly practiced in humans. However, the non-polymorphic nature of CD1 and MR1 proteins removes this key obstacle, so antigen-based T cell activation or polarization could be harnessed for therapy. Recent reviews document broad evidence that MAIT cells, CD1a-autoreactive T cells and NKT cells circulate in the blood and enter tissues in high numbers 8, 12, 117 . These cells secrete cytokines that have central roles in host defence and tissue repair 7, 112, 113, [117] [118] [119] . Lipid antigens such as αGalCer are bioavailable, and NKT cells can be activated and polarized in effector function by glycolipid antigens or altered glycolipid ligands 120, 121 . Although therapeutic outcomes have been limited, αGalCer induces consistent T cell responses in clinical trials, regardless of patient genetic background, with some encouraging results from recent small-scale cancer and vaccine trials 122, [123] [124] [125] . This early-stage work provides proof of principle to support more directed study of antigen formulation and administration.
Vitamin B derivatives, group 1 CD1-reactive antigens or non-permissive ligands have only been discovered recently, and so they have not entered clinical trials but might now also be tested in humans to stimulate, block or detect T cell responses. Antigens that control human CD1-reactive or MR1-reactive T cells offer promise for the development of new, 'one-size-fits-all' T cell immuno therapy approaches that are not possible with polymorphic antigen-presenting molecules.
